8-K: Akari Therapeutics Announces 1-for-40 ADS Reverse Split

Akari Therapeutics will implement a 1-for-40 reverse split of its American Depositary Shares to meet Nasdaq's minimum bid price requirement.

Summary

• Akari Therapeutics, Plc announced a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares.
• The ratio will change from one (1) ADS representing two thousand (2,000) ordinary shares to one (1) ADS representing eighty thousand (80,000) ordinary shares.
• This change will result in a one-for-forty reverse split of issued and outstanding ADSs.
• The ratio change is expected to be effective on or about March 31, 2026.
• The primary purpose of the ratio change is to enable the company to maintain compliance with the Nasdaq minimum bid price requirement for continued listing.
• The change will have no effect on the underlying ordinary shares.
• No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated, sold, and the net cash proceeds distributed to applicable ADS holders by Deutsche Bank.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing negatively due to the defensive nature of the reverse ADS split, which is a direct response to a potential Nasdaq delisting, and the explicit lack of assurance regarding its effectiveness.

Positives

• The ADS ratio change is intended to help Akari maintain its Nasdaq listing, preventing potential delisting.
• The company is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a novel RNA splice modulating payload (PH1).
• Akaris lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and has shown significant activity and prolonged survival in preclinical animal models, both as a single agent and in combination with checkpoint inhibitors.
• The PH1 payload has demonstrated activity against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, and FGFR3 fusions.
• The company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027.
• Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5, a well-validated tumor antigen.

Negatives

• The reverse ADS split is a defensive measure to avoid delisting from Nasdaq due to the company's share price failing to meet the minimum bid price requirement, indicating a low share price.
• The company explicitly stated it "can give no assurance that the Ratio Change will result in the Company satisfying and maintaining the minimum bid price requirement of Nasdaq."
• While the market price per ADS is expected to increase proportionally, there is no assurance of sustained performance or long-term compliance.

Risks

• The company's need for additional capital.
• The potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition, and losses on future prospects.
• Risks related to global and local political and economic conditions, including interest rate and currency exchange rate fluctuations.
• Potential delays or failures related to research and/or development of the company's programs or product candidates.
• Risks related to any loss of the company's patents or other intellectual property rights.
• Any interruptions of the supply chain for raw materials or manufacturing for product candidates, including as a result of potential tariffs.
• The nature, timing, cost, and possible success and therapeutic applications of product candidates being developed.
• The extent to which results from R&D programs may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval.
• Uncertainty of the utilization, market acceptance, and commercial success of the company's product candidates.
• Risks related to competition for the company's product candidates.
• The company's ability to successfully develop or commercialize its product candidates.
• No assurance that the ADS ratio change will result in the company satisfying and maintaining the Nasdaq minimum bid price requirement.

Future Outlook

The company aims to initiate its First-In-Human trial for AKTX-101 by late 2026/early 2027. The ADS ratio change is intended to help maintain Nasdaq listing, though there is no assurance of its long-term effectiveness in meeting minimum bid price requirements.

Management Comments

• "The ratio change is intended to enable Akari to maintain compliance with the Nasdaq minimum bid price requirement for continued listing."
• "The Company can give no assurance that the Ratio Change will result in the Company satisfying and maintaining the minimum bid price requirement of Nasdaq."

Industry Context

StockSavvy.ai notes that reverse stock splits are a common strategy for companies facing delisting from major exchanges like Nasdaq due to low share prices. While they can temporarily boost the per-share price to meet listing requirements, they do not fundamentally change the company's market capitalization or underlying value. The success of such a move in maintaining long-term compliance and investor confidence often depends on the company's ability to deliver on its strategic and clinical development goals, particularly for biotechnology firms like Akari.

Comparison to Industry Standards

• Reverse stock splits are generally viewed negatively in the biotechnology sector, often signaling underlying financial or operational challenges that have led to a depressed share price.
• Compared to successful biotech companies that maintain listing through strong clinical progress and commercialization, Akari's move indicates a struggle to meet basic exchange requirements.
• For example, companies like Moderna or BioNTech maintained strong share prices through successful clinical development and commercialization, avoiding such measures.
• The lack of assurance regarding maintaining Nasdaq compliance post-split is a significant concern, contrasting with companies that execute reverse splits from a position of relative strength or with clear, imminent positive catalysts.

Stakeholder Impact

• Shareholders (ADS holders) will experience a 1-for-40 reverse split of their ADSs, potentially increasing the per-share price but not the overall value of their holdings. Fractional entitlements will be sold for cash. The move aims to preserve Nasdaq listing, which is generally beneficial, but the underlying reason (low share price) is negative.

Next Steps

• The ADS ratio change will be effective on or about March 31, 2026.
• Deutsche Bank, the depositary bank, will arrange for the exchange of current ADSs for new ADSs.
• The company aims to start its First-In-Human trial for AKTX-101 by late 2026/early 2027, following initiated IND enabling studies.

Key Dates

Recommendation

The reverse ADS split is a strong indicator of severe share price weakness and a struggle to maintain basic exchange listing requirements. The explicit lack of assurance that this measure will even succeed in maintaining Nasdaq compliance, coupled with the inherent dilution risk from a stated "need for additional capital" (a risk factor), suggests significant underlying challenges. While the company has promising preclinical assets, the immediate corporate action points to a distressed situation, making the stock a high-risk "sell" for seasoned investors until fundamental improvements are demonstrated.

Keywords

Akari Therapeutics, AKTX, ADS Ratio Change, Reverse Split, Nasdaq Listing, Biotechnology, Oncology, Antibody Drug Conjugates, ADCs, RNA Splicing, PH1 Payload, AKTX-101, Trop2, AKTX-102, CEACAM5, Clinical Trials, IND Enabling Studies